Personalis, Inc. (PSNL)
NasdaqGM · Price as of · Nasdaq Real Time Price
- Analysts3
- Implied upside-5.4%
- Target range$13.00 to $16.25
- EPS expected-$0.25
- A year ago-$0.24
- Revenue expected$21.3M +47%
- Estimate range-$0.32 to -$0.23
SEC filings
Articles that mention Personalis without it being the main subject.
Tempus AI (TEM) rose 47% on a Merck and Moderna trial. Two analysts upgraded it after the run.
Cantor Fitzgerald initiated Tempus AI (TEM) at overweight with an $80 target, two days after Piper Sandler upgraded it. The 47% run both calls follow came from a Merck and Moderna Phase 3 readout, and the insider sales that made headlines were mostly automatic tax withholding.
Tempus AI (TEM) just turned its first profit. Its stock is still half off its high.
A deep dive on Tempus AI (TEM): what the cancer-data company does, its first quarterly profit, who controls the stock, the short-seller report against it, and why Wall Street can't agree on the price.
Frequently asked questions
When does PSNL report earnings?
Personalis, Inc. (PSNL) is scheduled to report quarterly results on November 3, 2026 (estimated). The 6-analyst consensus is -$0.25 per share on revenue of $21.3M for the quarter ended September 30, 2026, against -$0.24 and $14.5M a year earlier. It has beaten the consensus EPS estimate in 2 of the last four quarters. The date is an estimate from past reporting patterns and can move until the company confirms it.
What do analysts expect for PSNL?
3 analysts cover Personalis, Inc. (PSNL). The consensus rating is Hold. The average price target is $15.17, in a range of $13.00 to $16.25.
Are insiders buying or selling PSNL?
We have no qualifying Form 4 insider purchases or sales on record for Personalis, Inc. (PSNL). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see PSNL SEC filings?
We could not resolve current EDGAR filings for PSNL. This usually means the ticker is a foreign or over-the-counter listing that does not file with the SEC.